NCT02778100

A Study of Nasal Glucagon in Participants With a Common Cold

A Phase 1 Study to Evaluate the Effects of Common Cold and of Concomitant Administration of Nasal Decongestant on the Pharmacokinetics and Pharmacodynamics of a Novel Glucagon Formulation in Otherwise Healthy Subjects

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 36 (actual)
• Sponsor: Eli Lilly and Company · Industry
• Sex: All
• Age: 18 Years – 50 Years
• Healthy volunteers: Accepted

Summary

The main purpose of this study is to evaluate the safety of nasal glucagon (NG) in participants with a common cold, some of whom will also take a nasal decongestant. The study will investigate how the body processes NG and the effect of NG on the body. The study will last up to 30 days for each participant.

Conditions

• Common Cold

Interventions

Type	Name	Description
DRUG	Nasal Glucagon	Administered intranasally.
DRUG	Oxymetazoline	Administered intranasally.

Timeline

• Start date: 2013-03-01
• Primary completion: 2013-04-01
• Completion: 2013-04-01
• First posted: 2016-05-19
• Last updated: 2019-09-18
• Results posted: 2019-09-18

Locations

1 site across 1 country: Canada